IND clearance is a positive de-risking step but does not change the company's pre-revenue, going-concern status. Monitor for Phase II enrollment updates and any capital raise announcements, as the company will likely need additional funding to advance the trial.
Price Chart
Executive Summary
PRF Technologies announced FDA clearance of its IND application for OcuRing™-K, a sustained-release intraocular ring for post-cataract surgery pain and inflammation, enabling a Phase II trial expected to begin enrollment in H2 2026. This is an early-stage regulatory milestone for a pre-revenue micro-cap with no approved products and a going concern risk, providing limited near-term commercial value.
Key Facts
- FDA cleared IND for OcuRing™-K, a bio-erodible intraocular ring delivering ketorolac for cataract surgery pain/inflammation.
- Phase II multi-center trial planned in the U.S., with patient enrollment expected to begin in H2 2026.
- PRF has a $2M market cap, no approved products, and a going concern risk as noted in forward-looking statements.
- OcuRing™-K is developed through majority-owned subsidiary LayerBio, Inc.
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage company with $2M market cap.
Risk Factors
- Going concern risk: PRF has a history of losses and may need to raise capital, diluting existing shareholders.
- Phase II trial may fail to meet endpoints, delaying or ending the program.
- Micro-cap with low liquidity and high volatility; stock may not react significantly to early-stage regulatory milestones.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282536 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $0.7400 | awaiting T+60 | — | $0.7321 (−1.07%) |
Oct 23, 2026 4d ago | Press Release | $0.7400 | awaiting T+60 | — | $0.7321 (−1.07%) |
Sep 28, 2026 29d ago | 6-K | $0.9720 | awaiting T+60 | — | $0.7321 (−24.68%) |
Sep 24, 2026 4w ago | SC 13D | $0.9767 | awaiting T+60 | — | $0.7321 (−25.04%) |
Sep 16, 2026 5w ago | 6-K | $1.01 | awaiting T+60 | — | $0.7321 (−27.51%) |
Sep 4, 2026 7w ago | EFFECT | $0.9680 | awaiting T+60 | — | $0.7321 (+24.37%) |
Sep 3, 2026 7w ago | 6-K | $0.9792 | awaiting T+60 | — | $0.7321 (−25.23%) |
Sep 3, 2026 7w ago | Press Release | $0.9792 | awaiting T+60 | — | $0.7321 (−25.23%) |
Jul 27, 2026 13w ago | 6-K | $1.09 $0.7120 | ▼ −34.68% | ▼ −38.38% | $0.7321 (−32.83%) |
Jul 21, 2026 14w ago | 6-K | $1.20 $0.8180 | ▼ −31.83% | ▼ −35.81% | $0.7321 (−38.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers